Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 8/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2848749 | 1.00 | NR1H2 (0.41) | NR1H2MEN1KMT2ASRCCHRM2 | |
| SCHEMBL2839477 | 1.00 | NR1H2 (0.41) | NR1H2MEN1KMT2ASRCCHRM2 | |
| SCHEMBL25569891 | 0.88 | PARP1 (0.36) | NR1H2MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL20554158 | 0.86 | MEN1 (0.34) | NR1H2MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL20554159 | 0.86 | MEN1 (0.34) | NR1H2MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL32667153 | 0.86 | NR1H2 (0.40) | NR1H2MEN1KMT2A | |
| SCHEMBL8936130 | 0.83 | NR1H2 (0.42) | NR1H2MEN1KMT2ASRCCHRM2 | |
| SCHEMBL18700387 | 0.82 | TSHR (0.33) | NR1H2MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL585388 | 0.81 | MEN1 (0.32) | NR1H2MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL585387 | 0.81 | MEN1 (0.32) | NR1H2MEN1KMT2ACHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| WO-2023183405-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-4216946-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116437913-A | Pharmaceutical compounds for treating complement-mediated disorders | 艾其林医药公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-3458069-B1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS INC (US) | 2023-07-05 | — | — | EP | disclosed |
| EP-3458069-B1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS INC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-12 | — | — | US | disclosed |
| US-20230001001-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| WO-2022066774-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| US-20210393790-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-12-23 | — | — | US | disclosed |
| EP-2256120-A1 | Oxazolidinone-quinolone hybrids as antibacterial compounds | Actelion Pharmaceuticals Ltd. (CH) | 2010-12-01 | — | — | EP | disclosed |
| US-20100222302-A1 | Novel Antibacterial Compounds | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-02 | — | — | US | disclosed |
| US-20100069376-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-03-18 | — | — | US | disclosed |
| US-7189756-B2 | Pyrrolidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-20040242672-A1 | Useful as inhibitors of metalloproteases, e.g. zinc proteases; effective in treating disease states associated with vasoconstriction such as high blood pressure, coronary disorders, cardiac insufficiency, renal and myocardial ischaemia, renal insufficiency, dialysis, cerebral ischaemia | AEBI JOHANNES (CH) | 2004-12-02 | — | — | US | disclosed |
| US-6790860-B2 | USEFUL AS INHIBITORS OF METALLOPROTEASES, E.G. ZINC PROTEASES; EFFECTIVE IN TREATING DISEASE STATES ASSOCIATED WITH VASOCONSTRICTION | HOFFMANN-LA ROCHE INC. | 2004-09-14 | — | — | US | disclosed |
| US-20030199569-A1 | Pyrrolidine derivatives | AEBI JOHANNES (CH) | 2003-10-23 | — | — | US | disclosed |
| EP-1303486-A1 | PYRROLIDINE DERIVATIVES AS METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | disclosed |
| US-20020040146-A1 | Pyrrolidine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2002-04-04 | — | — | US | disclosed |
| WO-2002008185-A1 | PYRROLIDINE DERIVATIVES AS METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069376-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS | OGFOD1, ODC1, OXGR1 | NR1H2 299/4885MEN1 3048/4885KMT2A 1819/4885 |
| US-20230001001-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | CD4, MCL1, CCNB1 | NR1H2 3050/4885MEN1 106/4885KMT2A 1972/4885 |
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | DAO, DDO, DCLRE1A | NR1H2 4218/4885MEN1 2619/4885KMT2A 973/4885 |
| US-20030199569-A1 | Pyrrolidine derivatives | PREP, PEPD, MMP3 | NR1H2 3255/4885MEN1 3251/4885KMT2A 2324/4885 |
| US-20210393790-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | CD4, MCL1, CCNB1 | NR1H2 3050/4885MEN1 106/4885KMT2A 1972/4885 |
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C5, C1S, C9 | NR1H2 2093/4885MEN1 47/4885KMT2A 4601/4885 |
| US-20020040146-A1 | Pyrrolidine derivatives | PREP, PEPD, MMP3 | NR1H2 3255/4885MEN1 3251/4885KMT2A 2324/4885 |
| US-20100222302-A1 | Novel Antibacterial Compounds | ODC1, AOC1, OGFOD1 | NR1H2 367/4885MEN1 3273/4885KMT2A 2428/4885 |
| US-20040242672-A1 | Useful as inhibitors of metalloproteases, e.g. zinc proteases; effective in treating disease states associated with vasoconstriction such as high blood pressure, coronary disorders, cardiac insufficiency, renal and myocardial ischaemia, renal insufficiency, dialysis, cerebral ischaemia | MMP1, PEPD, MMP25 | NR1H2 2699/4885MEN1 2874/4885KMT2A 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.